PL2948157T3 - Zastosowanie genetycznie zmodyfikowanego zakaźnego wirusa odry o wzmocnionych właściwościach proapoptotycznych (wirusa MV-deltaC) w terapii nowotworów - Google Patents

Zastosowanie genetycznie zmodyfikowanego zakaźnego wirusa odry o wzmocnionych właściwościach proapoptotycznych (wirusa MV-deltaC) w terapii nowotworów

Info

Publication number
PL2948157T3
PL2948157T3 PL14701698T PL14701698T PL2948157T3 PL 2948157 T3 PL2948157 T3 PL 2948157T3 PL 14701698 T PL14701698 T PL 14701698T PL 14701698 T PL14701698 T PL 14701698T PL 2948157 T3 PL2948157 T3 PL 2948157T3
Authority
PL
Poland
Prior art keywords
virus
deltac
genetically modified
cancer therapy
apoptotic properties
Prior art date
Application number
PL14701698T
Other languages
English (en)
Polish (pl)
Inventor
Frédéric Tangy
Marc Gregoire
Jean-François Fonteneau
Jean-Baptiste Guillerme
Chantal Combredet
Original Assignee
Institut Pasteur
Centre National De La Recherche Scientifique (Cnrs)
Institut National de la Santé et de la Recherche Médicale
Université de Nantes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur, Centre National De La Recherche Scientifique (Cnrs), Institut National de la Santé et de la Recherche Médicale, Université de Nantes filed Critical Institut Pasteur
Publication of PL2948157T3 publication Critical patent/PL2948157T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18432—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18461—Methods of inactivation or attenuation
    • C12N2760/18462—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL14701698T 2013-01-24 2014-01-20 Zastosowanie genetycznie zmodyfikowanego zakaźnego wirusa odry o wzmocnionych właściwościach proapoptotycznych (wirusa MV-deltaC) w terapii nowotworów PL2948157T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13305086.4A EP2759301A1 (en) 2013-01-24 2013-01-24 Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus)
PCT/EP2014/051063 WO2014114605A1 (en) 2013-01-24 2014-01-20 Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (mv-deltac virus) in cancer therapy
EP14701698.4A EP2948157B1 (en) 2013-01-24 2014-01-20 Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (mv-deltac virus) in cancer therapy

Publications (1)

Publication Number Publication Date
PL2948157T3 true PL2948157T3 (pl) 2019-03-29

Family

ID=47683672

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14701698T PL2948157T3 (pl) 2013-01-24 2014-01-20 Zastosowanie genetycznie zmodyfikowanego zakaźnego wirusa odry o wzmocnionych właściwościach proapoptotycznych (wirusa MV-deltaC) w terapii nowotworów

Country Status (11)

Country Link
US (3) US9889193B2 (enExample)
EP (2) EP2759301A1 (enExample)
JP (1) JP6382223B2 (enExample)
CN (1) CN107223055A (enExample)
BR (1) BR112015017692B1 (enExample)
CA (1) CA2898370C (enExample)
DK (1) DK2948157T3 (enExample)
ES (1) ES2700749T3 (enExample)
PL (1) PL2948157T3 (enExample)
RU (1) RU2700083C2 (enExample)
WO (1) WO2014114605A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2759301A1 (en) * 2013-01-24 2014-07-30 Institut Pasteur Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus)
CN107085095A (zh) * 2017-03-02 2017-08-22 江苏华冠生物技术股份有限公司 用作酶联试剂盒包被抗原的麻疹病毒裂解液的制备方法
CA3082961A1 (en) * 2017-12-01 2019-06-06 Gerd Sutter Immuno-modulated replication-efficient vaccinia virus strain

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118740B1 (en) 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
PT1375512E (pt) 2002-06-20 2009-09-23 Pasteur Institut Adnc infeccioso de uma estirpe de vacina aprovada do vírus do sarampo. utilização de composições imunogénicas
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
CA2508266A1 (fr) 2005-06-20 2006-12-20 Institut Pasteur Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
ES2423518T3 (es) 2006-12-22 2013-09-20 Institut Pasteur Células y metodología para generar virus de ARN de cadena de sentido negativo no segmentada
EP2058003A1 (en) 2007-10-10 2009-05-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Medicaments and methods for treating mesothelioma
EP2420242A1 (en) * 2010-08-20 2012-02-22 Lauer, Ulrich M. Oncolytic measles virus
US9399062B2 (en) * 2011-01-18 2016-07-26 Christopher D. Richardson PVRL4 (Nectin4) is a receptor for measles virus
EP2759301A1 (en) * 2013-01-24 2014-07-30 Institut Pasteur Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus)

Also Published As

Publication number Publication date
DK2948157T3 (en) 2019-01-07
US9889193B2 (en) 2018-02-13
BR112015017692A2 (pt) 2019-11-19
US10314905B2 (en) 2019-06-11
ES2700749T3 (es) 2019-02-19
BR112015017692B1 (pt) 2021-11-03
US20180221469A1 (en) 2018-08-09
US10980873B2 (en) 2021-04-20
US20200016260A1 (en) 2020-01-16
CN107223055A (zh) 2017-09-29
CA2898370C (en) 2020-01-14
EP2948157B1 (en) 2018-10-10
CA2898370A1 (en) 2014-07-31
EP2948157A1 (en) 2015-12-02
WO2014114605A1 (en) 2014-07-31
JP6382223B2 (ja) 2018-08-29
RU2700083C2 (ru) 2019-09-12
EP2759301A1 (en) 2014-07-30
JP2016506722A (ja) 2016-03-07
RU2015128913A (ru) 2017-03-02
US20150359873A1 (en) 2015-12-17

Similar Documents

Publication Publication Date Title
IL264385B (en) Newcastle disease viruses and their use
IL261204A (en) Influenza virus vaccines and their use
IL244254A0 (en) Engineered anti-dll3 conjugates and methods of use
IL244665B (en) Conjugates of chlorotoxin and methods of using them
IL245312B (en) Recombinant oncolytic herpes simplex virus
ZA201509229B (en) Influenza virus vaccines and uses thereof
SG11201602838UA (en) Safe socket and use thereof
DK2903600T3 (da) Virusholdig formulering og anvendelse deraf
HUE047912T2 (hu) Bilirubin részecskék és elõállításuk terápia során történõ alkalmazásra
HUE043463T2 (hu) Vírusszerû részecske konjugátumok tumorok kezelésére
ZA201501639B (en) Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
PL2935313T3 (pl) Szczepionki przeciwko wirusowi zapalenia wątroby typu b
ZA201701643B (en) Pyrrolopyrimidines for use in influenza virus infection
EP3046565A4 (en) Papaya mosaic virus and virus-like particles in cancer therapy
EP2806890A4 (en) COMPOSITIONAL ANTIGEN SEQUENCES AND VACCINES
PL2969005T3 (pl) Atenuowane wirusy grypy i szczepionki
IL244750A0 (en) Autologous tumor vaccines and methods
EP3049112A4 (en) Influenza vaccine and therapy
SG11201604301VA (en) Piperidine and piperazine derivatives and their use in treating viral infections and cancer
SG11201509265SA (en) Avoiding narcolepsy risk in influenza vaccines
PL2948157T3 (pl) Zastosowanie genetycznie zmodyfikowanego zakaźnego wirusa odry o wzmocnionych właściwościach proapoptotycznych (wirusa MV-deltaC) w terapii nowotworów
CL2015003706A1 (es) Composiciones vacunales bivalentes y su uso para la terapia de tumores
EP3068411A4 (en) Oncolytic viruses and increased cancer treatment regimens
GB201301119D0 (en) Viral vaccines
SG11201507455WA (en) Hepatitis b virus vaccines